



Vivimed

For Immediate Release

May 10, 2021

**Vivimed announces the receipt of Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market**

Hyderabad, India, May 10, 2021 – Vivimed Labs Limited (“Vivimed” or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the receipt of Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg under Vivimed’s own brand name “Favulous” across India. It is used for the treatment of mild to moderate cases of Covid-19 . Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.

Favipiravir registered highest sales in the month of April 2021. To register as top pharma brand in the domestic market(Fabiflu:Glenmark:762 Crores)

\*\*\* \*\*

Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, “With huge spike in Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19.”

The company will work closely with the various governments and medical community to ensure availability of “Favulous” to patients across the Country.

For further information on Vivimed, visit [www.vivimedlabs.com](http://www.vivimedlabs.com)

\*\*\* \*\*

**Safe Harbour**

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

**Company Contact:**

K.Yugandhar  
Company Secretary & Compliance officer  
Vivimed Labs Limited (CIN No: L02411KA1988PLC009465)  
Corporate office: Northend Complex, Road No.2,Banjara Hills, Hyderabad,India  
Phone: 040-66086608, Email: [yugandhar.kopparthi@vivimedlabs.com](mailto:yugandhar.kopparthi@vivimedlabs.com)

For VIVIMED LABS LTD.

*K. Yugandhar*  
Company Secretary

